Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CELECOXIB

All products: Limited Use (codes 316, 317)

Other products in the same Health Canada class (M01A) — coverage varies; not interchangeable

  • Diclofenac (Voltaren): general benefit, Not a benefit
  • Diclofenac + misoprostol (Arthrotec 50): general benefit
  • Flurbiprofen (Ansaid): general benefit, Not a benefit
  • Ibuprofen (Motrin): general benefit, Not a benefit
  • Indomethacin (Indocid): general benefit, Not a benefit
  • Ketoprofen (Ketoprofen): general benefit, Not a benefit

12 more in the class list below

Celebrex · DIN 02239941 · 100mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 316, 317 required
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Savings card: RxHelp ONE lists Celebrex (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Celebrex · DIN 02239941 Manufacturer: Upjohn Canada ULC; listing date 2000-04-17 Health Canada: Marketed since 2023-09-26 · brand CELEBREX · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 100 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1279 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63442 · Verify on the e-Formulary ↗ (DIN 02239941)

Source record
DIN 02239941: Celebrex Raw flags: sec12=Y, sec3=Y Item: 280804075; group id 377; item number 0898; lccId 00064; manufacturer id UJC Source form: Cap; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.8482; ministry $0.1279 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239941 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63442 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437570 · $0.1279 Act Celecoxib · DIN 02420155 · $0.1279 Apo-Celecoxib · DIN 02418932 · $0.1279 Auro-Celecoxib · DIN 02445670 · $0.1279 Bio-Celecoxib · DIN 02426382 · $0.1279 Celecoxib · DIN 02429675 · $0.1279 Celecoxib · DIN 02436299 · $0.1279 Jamp-Celecoxib · DIN 02424533 · $0.1279 M-Celecoxib · DIN 02495465 · $0.1279 Mar-Celecoxib · DIN 02420058 · $0.1279 Mint-Celecoxib · DIN 02412497 · $0.1279 NRA-Celecoxib · DIN 02479737 · $0.1279 PMS-Celecoxib · DIN 02355442 · $0.1279 PMSC-Celecoxib · DIN 02517116 · $0.1279 Ran-Celecoxib · DIN 02412373 · $0.1279 Sdz Celecoxib · DIN 02442639 · $0.1279 Teva-Celecoxib · DIN 02288915 · $0.1279
Shortage status: resolved shortage (ended 2017-06-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239941
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:08:04 Nonsteroidal Anti-Inflammatory Agents) and how they are covered

Matched class: 28:08:04 Nonsteroidal Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DICLOFENAC SODIUM & MISOPROSTOL Some products covered without a code (check the product listing): DICLOFENAC SODIUM, FLURBIPROFEN, IBUPROFEN, INDOMETHACIN, KETOPROFEN, MEFENAMIC ACID, MELOXICAM, NAPROXEN, PIROXICAM, SULINDAC, TIAPROFENIC ACID 28:08:04 Nonsteroidal Anti-Inflammatory Agents

DICLOFENAC SODIUM

· 19 products · Listed, not a benefit (3), General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 25mg, 50mg, 75mg, 100mg, 1.5% W/W · Ent Tab, LA Tab, Sup, Top Sol

DICLOFENAC SODIUM & MISOPROSTOL

· 6 products · General benefit · strengths: 50mg & 200mcg, 75mg & 200mcg · Tab

FLURBIPROFEN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50mg, 100mg · Tab

IBUPROFEN

· 11 products · Listed, not a benefit (3), General benefit (8) · strengths: 200mg, 300mg, 400mg, 600mg · Tab

INDOMETHACIN

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 25mg, 50mg, 100mg · Cap, Sup

KETOPROFEN

· 9 products · General benefit (4), Listed, not a benefit (5) · strengths: 50mg, 100mg, 200mg · Cap, Ent Tab, LA Tab

MEFENAMIC ACID

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Cap

MELOXICAM

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 7.5mg, 15mg · Tab

NAPROXEN

· 21 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (8), Listed, not a benefit (4) · strengths: 250mg, 375mg, 500mg, 25mg/mL, 125mg · Ent Tab, O/L, Tab

PIROXICAM

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 10mg, 20mg · Cap

SULINDAC

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 150mg, 200mg · Tab

TIAPROFENIC ACID

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 200mg, 300mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:08:04 and 6 more
Full class listing Related classes: 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: pain
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE · General benefit (2), Listed, not a benefit (2) INDICATIONS AND CLINICAL USE Adults TEVA-LENOLTEC No. 2 and No. 3 (acetaminophen, caffeine and codeine phosphate) are indicated for the short-term relief of mild to moderate pain. PM: https://pdf.hres.ca/dpd_pm/00065848.PDF; date July 15, 2014; DIN 00653241; fetched 2026-09-10 Product monograph BUTORPHANOL TARTRATE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS Adults BUTORPHANOL Nasal Spray (butorphanol tartrate) is indicated for: • the relief of moderate to severe acute pain. PM: https://pdf.hres.ca/dpd_pm/00069311.PDF; date MAR 24, 2015; DIN 02242504; fetched 2026-09-10 Product monograph CODEINE SULFATE TRIHYDRATE & MONOHYDRATE · Limited Use, codes 201 1 Indications CODEINE CONTIN (codeine controlled release tablets) is indicated for the relief of mild to moderate pain in adults requiring the prolonged use of an opioid analgesic preparation. PM: https://pdf.hres.ca/dpd_pm/00078791.PDF; date 2025-03-04; DIN 02163748; fetched 2026-09-10 Product monograph HYDROMORPHONE HCL · General benefit (21), Listed, not a benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4) 1 INDICATIONS DILAUDID® (HYDROmorphone hydrochloride) is indicated for the relief of moderate to severe pain in adults. 1.1 Pediatrics No data are available to Health Canada. PM: https://pdf.hres.ca/dpd_pm/00072218.PDF; date August 29, 2023; DIN 00125083; fetched 2026-09-10 Product monograph OXYCODONE HCL · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS Supeudol® 5 (oxycodone hydrochloride tablets) / Supeudol® 10 (oxycodone hydrochloride tablets) is indicated for: • relief of moderate to severe pain. PM: https://pdf.hres.ca/dpd_pm/00080231.PDF; date not captured; DIN 00443948; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS CELEBREX (celecoxib capsules) is indicated for relief of symptoms associated with: • Osteoarthritis, • Adult Rheumatoid Arthritis, and • Ankylosing Spondylitis CELEBREX is also indicated for the short-term ( 7 days) management of moderate to severe acute pain in adults in conditions such as the following: • Musculoskeletal and/or soft tissue trauma including sprains, • Postoperative orthopaedic, and • Pain following dental extraction CELEBREX, particularly at doses higher than 200 mg per day, is associated with an increased risk of serious cardiovascular related adverse events (such as myocardial infarction, stroke or thrombotic events), which can be fatal. Doses of CELEBREX > 200 mg/day should NOT be used in patients with ischemic heart disease, cerebrovascular disease, patients with congestive heart failure (NYHA II-IV) or patients with risk factors for cardiovascular disease. For patients with an increased risk of developing cardiovascular adverse events, other management strategies that do NOT include the use of NSAIDs, particularly celecoxib, diclofenac, or ibuprofen, should be considered first (see 2 CONTRAINDICATIONS and 7 WARNINGS… https://pdf.hres.ca/dpd_pm/00080998.PDF PM date: 2025-07-09 Source product: CELEBREX; DIN 02239941; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.